The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
Official Title: A Pre-Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer
Study ID: NCT01864798
Brief Summary: This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be collected at baseline and at surgery. Post-operative treatment will be at the discretion of the investigator. Primary objective: to determine if a short course of RANKL inhibition with denosumab can induce a decrease in tumor proliferation rates as determined by Ki67 immunohistochemistry (IHC) in newly diagnosed, early stage breast cancer in pre-menopausal women. Secondary objectives: * To determine the number of absolute Ki67 responders after a short course of denosumab (defined as \<2.7% IHC staining in the post treatment tumor biopsy). * To determine the effects of a short course of denosumab on serum C-terminal telopeptide levels (CTX). * To determine the effects of a short course of denosumab on RANK/RANKL gene expression and signaling as assessed by immunohistochemistry (IHC) and RNA sequencing in the tumor. * To determine the effect of a short course of denosumab on tumor apoptosis rates using IHC * To determine the effect of a short course of denosumab on modulating the immature mammary epithelial cell populations in the tumor. * To determine the effect of a short course of denosumab on estrogen signaling pathways in the tumor. * To determine the effect of a short course of denosumab on various immune * To determine effect of safety profile of denosumab
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Royal Melbourne Hospital, Victoria, , Australia
Institute Jules Bordet, Brussels, , Belgium
Hopital Erasme, Brussels, , Belgium
UZ Leuven, Leuven, , Belgium
CHU Ambroise Paré, Mons, , Belgium
CMSE, Namur, , Belgium
Name: Martine J Piccart, Prof.
Affiliation: Jules Bordet Institute
Role: STUDY_CHAIR
Name: Christos Sotiriou, MD
Affiliation: Jules Bordet Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Hatem Azim, MD
Affiliation: Jules Bordet Insitute
Role: PRINCIPAL_INVESTIGATOR
Name: Sherene Loi, MD,PhD
Affiliation: Melbourne Health
Role: PRINCIPAL_INVESTIGATOR